Evidence map›Paper›PMID 36890448›Full record

ArticleBMC infectious diseases2023

Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.

Maile T Phillips, Marina Antillon, Joke Bilcke, Naor Bar-Zeev, Fumbani Limani, Frédéric Debellut, Clint Pecenka, Kathleen M Neuzil, Melita A Gordon, Deus Thindwa and 3 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maile T PhillipsDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA.ORCID http://orcid.org/0000-0001-6952-0440
Marina AntillonSwiss Tropical and Public Health Institute, Basel, Switzerland.
Joke BilckeCenter for Health Economics Research and Modeling Infectious Diseases, University of Antwerp, Antwerp, Belgium.
Naor Bar-ZeevInternational Vaccine Access Center, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Fumbani LimaniMalawi Liverpool Wellcome Programme, Blantyre, Malawi.
Frédéric DebellutCenter for Vaccine Innovation and Access, PATH, Geneva, Switzerland.
Clint PecenkaCenter for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
Kathleen M NeuzilCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Melita A GordonMalawi Liverpool Wellcome Programme, Blantyre, Malawi.
Deus ThindwaMalawi Liverpool Wellcome Programme, Blantyre, Malawi.
A David PaltielDepartment of Health Policy, Yale School of Public Health, New Haven, CT, USA.
Reza YaesoubiDepartment of Health Policy, Yale School of Public Health, New Haven, CT, USA.
Virginia E PitzerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA. virginia.pitzer@yale.edu.

Funding

Bill and Melinda Gates Foundation OPP1151153
6 · The paper itself

Abstract

backgroundSeveral prolonged typhoid fever epidemics have been reported since 2010 throughout eastern and southern Africa, including Malawi, caused by multidrug-resistant Salmonella Typhi. The World Health Organization recommends the use of typhoid conjugate vaccines (TCVs) in outbreak settings; however, current data are limited on how and when TCVs might be introduced in response to outbreaks. METHODOLOGY: We developed a stochastic model of typhoid transmission fitted to data from Queen Elizabeth Central Hospital in Blantyre, Malawi from January 1996 to February 2015. We used the model to evaluate the cost-effectiveness of vaccination strategies over a 10-year time horizon in three scenarios: (1) when an outbreak is likely to occur; (2) when an outbreak is unlikely to occur within the next ten years; and (3) when an outbreak has already occurred and is unlikely to occur again. We considered three vaccination strategies compared to the status quo of no vaccination: (a) preventative routine vaccination at 9 months of age; (b) preventative routine vaccination plus a catch-up campaign to 15 years of age; and (c) reactive vaccination with a catch-up campaign to age 15 (for Scenario 1). We also explored variations in outbreak definitions, delays in implementation of reactive vaccination, and the timing of preventive vaccination relative to the outbreak.

resultsAssuming an outbreak occurs within 10 years, we estimated that the various vaccination strategies would prevent a median of 15-60% of disability-adjusted life-years (DALYs). Reactive vaccination was the preferred strategy for WTP values of $0-300 per DALY averted. For WTP values > $300, introduction of preventative routine TCV immunization with a catch-up campaign was the preferred strategy. Routine vaccination with a catch-up campaign was cost-effective for WTP values above $890 per DALY averted if no outbreak occurs and > $140 per DALY averted if implemented after the outbreak has already occurred.

conclusionsCountries for which the spread of antimicrobial resistance is likely to lead to outbreaks of typhoid fever should consider TCV introduction. Reactive vaccination can be a cost-effective strategy, but only if delays in vaccine deployment are minimal; otherwise, introduction of preventive routine immunization with a catch-up campaign is the preferred strategy.

Indexed as

Typhoid FeverTyphoid-Paratyphoid VaccinesAdolescentCost-Benefit AnalysisCost-Effectiveness AnalysisHumansVaccines, ConjugateTyphoid-Paratyphoid VaccinesVaccines, ConjugateEconomic evaluationPreventive vaccinationReactive vaccinationTyphoid conjugate vaccinesTyphoid fever

Identifiers

PMID36890448
PMCPMC9993384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.